Penumbra (PEN) Long-Term Investments (2017 - 2018)

Penumbra (PEN) reported Long-Term Investments of $2.6 million for Q2 2018, down 20.97% quarter-over-quarter from $3.3 million in Q1 2018.

Penumbra (PEN) Long-Term Investments (2017 - 2018) Analysis & Trends

Penumbra (PEN) has 2 years of Long-Term Investments data on file, last reported at $2.6 million in Q2 2018.

Long-Term Investments for Q2 2018 came in at $2.6 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2018 was $2.6 million (changed N/A YoY), and the FY2017 annual result was $3.9 million, changed N/A from the prior year.
Long-Term Investments retreated to $2.6 million in Q2 2018 per PEN's latest filing, from $3.3 million in the prior quarter.
Over five years, Long-Term Investments peaked at $3.9 million in Q4 2017 and troughed at $2.6 million in Q2 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Abbott Laboratories	152.92 Bn	146.27 Bn	6.27 Bn	1.09 Bn
2	Stryker	119.50 Bn	116.62 Bn	3.81 Bn	-
3	Medtronic	102.71 Bn	94.54 Bn	5.76 Bn	-
4	Boston Scientific	69.72 Bn	68.51 Bn	3.61 Bn	-
5	Edwards Lifesciences	49.24 Bn	45.57 Bn	1.29 Bn	285.60 Mn
6	GE HealthCare Technologies	29.74 Bn	27.67 Bn	1.98 Bn	-
7	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	166.25 Mn
8	Dexcom	28.96 Bn	27.84 Bn	750.30 Mn	-
9	Steris	20.31 Bn	19.88 Bn	697.10 Mn	-
10	Penumbra	12.51 Bn	11.90 Bn	253.41 Mn	-

Download Data